Correlation between classic driver oncogene mutations in EGFR ALK or ROS1 and 22C3-PD-L1 ≥50 expression in lung adenocarcinoma

摘要

IntroductionTargeted somatic genomic analysis (EGFR, ALK and ROS1) and PD-L1 tumor proportion score (TPS) by immunohistochemistry (IHC) are used for selection of 1^st-line therapies in advanced lung cancer; however, the frequency of overlap of these biomarkers in routine clinical practice is poorly reported.